Fig. 3
From: JNK signaling provides a novel therapeutic target for Rett syndrome
D-JNKI1 effect against dendritic spine alterations in Mecp2y/- male mice. a Western blots and quantifications in the cerebellum TIF (post-synaptic elements) of treated and untreated wt and Mecp2y/- mice to measure D-JNKI1 effect in vivo. D-JNKI1 significantly reduced JNK activation in Mecp2y/- mice, but not in control wt mice. b Western blots and quantifications of the post-synaptic elements in the cerebellum showed normalization of the PSD markers levels to control level in D-JNKI1-treated compared to untreated Mecp2y/- mice (n=10 for each experimental group). Data were shown as mean ± SEM. Significance was calculated using two‐way ANOVA followed by Bonferroni post hoc test. Significance relative to control *p<0.05, **p<0.01, and ****p<0.0001. D-JNKI1-treated vs untreated Mecp2y/− #p< 0.05, ##p< 0.01, ###p<0.001, and ####p<0.0001